fda compounding semaglutide warning letters october 2025 Troubling Findings in Study of GLP-1 Compounders FDA is moving to restrict

GLP-1 receptor agonists are peptide-based biologics that are absorbed directly into the systemic circulation from subcutaneous tissue, making them independent of intestinal absorption processes that might be affected by altered bile flow

Retatrutide is a triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, whereas semaglutide acts on GLP-1 receptors alone and tirzepatide targets both GIP and GLP-1 receptors

They mostly compound only if theres a real medical reason, like a patient allergy

FOR PEOPLE WITH DIABETES ARE ABOUT 20 PERCENT MORE LIKELY TO EXPERIENCE ANXIETY SOURCE: Centers for Disease Control and Prevention

Semaglutide GLP-1 injection treatment length will likely vary for every patient as each person is very different